Inclusion Criteria:

- Male or female, age ≥ 18 yrs and ＜70 yrs with histologically or cytologically
confirmed

- Malignant disease

- Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60

- Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin
60 ~ 80 mg/m2 on study Day 1

- Use of reliable contraceptive measures (for females of childbearing potential) and
negative pregnancy test at baseline visit

- Patients with hepatic, renal, or cardiovascular impairment eligible at the
investigator's discretion

- Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible
at the investigator's discretion

- Predicted life expectancy of ≥ 3 months

- Provision of written informed consent.

Exclusion Criteria:

- Inability to understand or cooperate with study procedures

- Receipt of investigational drugs ≤ 30 days before study entry

- Receipt of other investigational drugs during the course of this study

- Seizure disorder or any condition requiring anticonvulsants, sedatives

- CNS malignancy or metastasis

- Ongoing emesis due to obstruction of digestive tract

- Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy

- Moderate or severe nausea and vomiting after any previous chemotherapy

- Scheduled receipt of any chemotherapeutic agent with an emetogenicity level ＞3 during
study Days 2-5

- Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 2-5

- Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of
study initiation and throughout day 5

- Contraindications to 5-HT3 receptor antagonists

- Contraindications to chemotherapy